IBA Health has had a mixed year. It has shown a profit this year and thought it had made a significant deal in the UK market for distributing its products. This has become un-stuck with the iSoft/Torex merger plan but IBA has solidified its position in Asia and in its home markets. The company needs to rapidly attract the right partners globally and create a much stronger ecosystem. It claims to be more focused on the Asian markets but needs to be a player globally. The company also needs to continue its focus on earnings this year and continue with its acquisition program.

Note: TekPlus Points state the current opinion of the vendor as viewed by TekPlus. TekPlus experts take a number of parameters into account when analysing a vendor and its position in the competitive landscape going forward. The scale of the points are as follows; +3 : Extremely Solid Position, +2 : Solid Position, +1 : Promising Position, 0 : Weak Position and -1 : Very Weak Position.